Core Insights - CareCloud, Inc. is participating in the "2025 Virtual Tech Conference" to discuss the impact of AI on healthcare delivery [1][2] - The conference will highlight how emerging growth companies are utilizing transformative technologies like AI and Quantum Computing for long-term success [3] Company Overview - CareCloud specializes in AI-driven healthcare technology solutions, aiming to enhance financial and operational performance, streamline clinical workflows, and improve patient experiences [4] - The company serves over 40,000 providers, focusing on reducing administrative burdens and operating costs while improving patient care [4] Conference Details - The Healthcare IT Panel featuring CareCloud is scheduled for June 3, 2025, at 11:00 a.m. EDT [1] - Participants must register as M-Vest members to attend the conference and view CareCloud's presentation [3]

Core Insights - The Agfa-Gevaert Group reported stable adjusted EBITDA in Q1 2025 compared to Q1 2024, with improved sales mix and effective cost control offsetting declines in traditional film markets [1][5][10]. Financial Performance - Total revenue decreased by 3.2% from €250 million in Q1 2024 to €242 million in Q1 2025 [4][10]. - Adjusted EBITDA remained stable at €2 million, representing 0.9% of revenue, up from 0.7% in Q1 2024 [4][10]. - The net loss for the period was €20 million, slightly improved from a loss of €21 million in Q1 2024 [4][10]. Division Performance HealthCare IT - Revenue increased by 12.0% to €57 million, with adjusted EBITDA rising from €1.3 million to €5.0 million [2][9]. - The division saw a 63% increase in rolling order intake over 12 months, with a significant share from new customers and cloud-related contracts [11]. - Gross profit margin improved from 43.8% to 47.9% [11]. Digital Print & Chemicals - Revenue grew by 5.8% to €97 million, with adjusted EBITDA increasing from €1.0 million to €2.3 million [13][17]. - Ink sales rose by 16%, although equipment sales were affected by a weaker investment climate [17]. Radiology Solutions - Revenue declined by 15.6% to €73 million, with adjusted EBITDA dropping to -€4.5 million [15][16]. - The division faced challenges due to a significant decline in medical film markets, particularly in China [5][10]. Contractor Operations - Revenue decreased by 29.1% to €15 million, with adjusted EBITDA down by 30.6% [18]. Outlook - The company expects continued strong performance from growth engines in 2025, with a stronger second half anticipated due to seasonal factors [8][10]. - Cost optimization measures for traditional film activities are expected to yield initial savings in the second half of 2025 [1][5].

SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) ("CareCloud" or the "Company"), a leader in healthcare technology and generative AI solutions, today announced that Maxim Group, LLC ("Maxim Group"), a leading investment bank, securities and wealth management firm, has selected CareCloud as its "Top Healthcare IT Pick for 2025," citing the transformative potential of its artificial intelligence strategy, together with its strong financial results and renewed M&A activity ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $270 million, an increase of $24 million from Q1 2024, but a decrease of $37 million from Q4 2024 [6][15][19] - Product revenues were $145 million, up $12 million year-over-year but down $37 million sequentially [7][16] - Service revenues were $125 million, an increase of $12 million from the previous year and flat compared to the prior quarter [7][16] - Non-GAAP gross margin for Q1 2025 was 42.1%, a decrease of 530 basis points from the prior quarter [7][16] - Non-GAAP earnings per share for Q1 2025 was $0.26, compared to $0.03 in the same period last year and $0.60 in the prior quarter [8][17] - Non-GAAP EBITDA was $24 million, an increase of $13 million year-over-year but a decrease of $23 million from the previous quarter [8][18] Business Line Data and Key Metrics Changes - The XT Amplify program contributed to revenue growth, alongside SaaS and XPath services, particularly in specialty pharmacy services [15][16] - The company continues to see strong customer interest in its long-term innovation roadmap, particularly in medication management solutions [5][6] Market Data and Key Metrics Changes - The demand environment tracked well with expectations, showing market share gains and continued interest in the company's product offerings [5][6] - The company is focused on expanding its market share across inpatient and outpatient settings, including specialty and retail pharmacies [5][6] Company Strategy and Development Direction - The company aims to capture greater market share in various healthcare settings and grow its predictable recurring revenue [5][6] - The strategy includes expanding the Omnisphere cloud-based platform and integrating AI technologies across the continuum of care [5][6] - The company is committed to optimizing its supply chain and mitigating tariff impacts through dual sourcing and near-shoring efforts [9][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the current tariff environment and emphasized the importance of supply chain optimization [9][13] - The company remains optimistic about long-term growth strategies aligning with the vision of the Autonomous Pharmacy [13][27] - Management noted that the first quarter typically has the lowest revenue and profitability, with expectations for growth throughout the year [17][19] Other Important Information - The anticipated impact from tariffs for 2025 is approximately $40 million to non-GAAP EBITDA, leading to adjustments in guidance [9][24] - The company continues to generate solid free cash flow, with cash and cash equivalents at $387 million as of Q1 2025 [19][20] Q&A Session Summary Question: Can you describe the outlook for tariff distribution between Omnicell and customers? - Management indicated that currently, they are not passing significant price increases to customers but may adjust discounts in the future [30][31] Question: What is the cadence of the $40 million tariff impact? - The total impact is expected to be $40 million for the year, with about $5 million in Q2 and the remainder in the second half, particularly in Q4 [36][38] Question: Are there any fundamentals driving reacceleration in demand for pharmacy IT? - Management noted that specialty pharmacy is a top topic among providers, leading to more strategic discussions about revenue generation and operational efficiency [45][47] Question: What are the assumptions behind the new EBITDA guidance range? - The guidance changes account for tariffs, with mitigation actions including relocating supply chains and evaluating pricing strategies [52][56] Question: How long will it take to reduce supply chain exposure to China? - Management stated that while some components will still flow through China, they are taking actions to move sourcing to other regions over time [63][64] Question: How is the hospital buying environment characterized? - Management reported no slowdown in revenue or installation processes, indicating a positive environment despite potential macroeconomic challenges [80][84]

Financial Data and Key Metrics Changes - As of January 31, 2025, the company reported total revenue of $17.9 million for the twelve months ended, down from $22.6 million in the previous fiscal year [14] - The net loss for the fourth quarter of fiscal 2024 was $2.1 million, compared to a net loss of $1.4 million in the same quarter of the previous year [16] - Cash and cash equivalents decreased to $2.2 million as of January 31, 2025, from $3.2 million a year earlier [17] Business Line Data and Key Metrics Changes - Booked SaaS Annual Contract Value (ACV) was $14 million as of January 31, 2025, and increased to $14.6 million by April 30, 2025 [14][16] - SaaS revenue for the fourth quarter of fiscal 2024 was $3.1 million, representing 66% of total revenue, down from $3.4 million or 64% in the same quarter of the previous year [16] Market Data and Key Metrics Changes - The company experienced a churn of $700,000 primarily due to two clients lost to acquisitions [7] - The denial prevention functionality is expected to significantly enhance the financial impact of the eValuator platform, potentially increasing inpatient financial impact by over 15% and doubling the impact on outpatient cases [10] Company Strategy and Development Direction - The company has decided to discontinue selling its quality module as an independent unit to focus resources on initiatives that expand the core value proposition [9] - The launch of the denial prevention functionality is seen as timely, addressing the surge in denial activity from commercial payers [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving an EBITDA profitable run rate during the first half of fiscal 2025 [14] - The company is focusing on enhancing client relationships and leveraging successful client stories to drive bookings [28] Other Important Information - The company amended certain financial covenants related to its senior term loan and revolving line of credit on March 28, 2025 [17] - The implementation timeline for eValuator has improved significantly, with recent implementations completed in as little as 42 days [26] Q&A Session Summary Question: Can you talk about the denials prevention product and its marketability? - Management highlighted the importance of integrating denial signals into the pre-bill workflow to enhance claim accuracy, which clients find immensely valuable [22][23] Question: What changes have enabled quicker implementations? - The company has standardized data and training processes, significantly reducing implementation times from four to six months to two to three months [27] Question: What gives confidence in building momentum for bookings? - Management noted increased top-of-funnel activity driven by client success stories and recent events, indicating a positive trend in bookings [28][29]

Core Insights - Epic Systems achieved its largest net gain in hospital market share in 2024, surpassing Oracle [1] - Epic added 176 facilities and 29,399 beds, while Oracle lost 74 sites and 17,232 beds during the same period [2] - Oracle's failure to share new contract details with Klas Research marks a significant shift in its market strategy [2] Company Performance - Epic's reputation for customer partnership has positioned it favorably in the EHR market [2] - Oracle's recent technological advancements, including AI features, have generated cautious optimism among stakeholders [4] - Oracle's EHR software has faced challenges, including outages and deployment issues, impacting its market perception [6][7] Market Dynamics - The EHR market is heavily influenced by vendor partnerships and customer satisfaction, with Epic consistently chosen by large health systems [7] - Oracle's acquisition of Cerner for approximately $28 billion in 2022 positioned it as the second-largest EHR vendor [3] - Recent comments from Oracle's founder suggest the company believes it is in a favorable position despite current challenges [4][5]

Industry Overview - Healthcare IT spending is on the rise, with 75% of healthcare providers increasing investments in AI, cybersecurity, and other IT areas, transitioning from a pandemic response to a core aspect of next-generation healthcare driven by generative AI technologies [1][2] - The sector is projected to experience a compound annual growth rate (CAGR) of 15.4% from 2024 to 2031, making healthcare IT a highly attractive investment opportunity [2] Company Highlights - Tempus AI has seen its stock rise by 30% year-to-date, focusing on precision oncology and personalized care through its AI-based platform that integrates multi-modal data [7] - Butterfly Network is gaining traction with its Ultrasound-on-Chip technology and is expected to report 5.9% earnings growth alongside an 18.9% revenue increase in 2025, with a strong buy recommendation from brokers [12][13] - Health Catalyst provides data and analytics technology to improve healthcare outcomes, with expectations of 7.1% earnings growth and a 9.2% revenue increase in 2025, holding a "hold" rating from analysts [18][19] Digital Transformation - By 2025, 70% of healthcare leaders plan to invest in digital tools, with 60% aiming to upgrade core technologies like EMRs and ERP software, indicating a significant shift towards digital transformation in the industry [9] - Cybersecurity is a major focus, with 78% of executives prioritizing enhancements due to the increasing risk of cyber threats as digital adoption accelerates [10] Generative AI Impact - Over 40% of organizations report significant to moderate returns on investment from generative AI, while 37% are still evaluating its impact, suggesting many companies are in the early stages of implementation [11]

Core Insights - Strata Decision Technology collaborates with Snowflake to create one of the largest comparable healthcare financial databases in the U.S., aiming to provide efficient access to near real-time and historical financial insights [1][2] Group 1: Collaboration and Data Integration - The partnership allows Strata to unify diverse data assets, including financial, operational, clinical, cost and margin, and claims data, within Snowflake's cloud platform, eliminating data siloes [2][3] - Strata is integrating multiple high-value datasets into Snowflake, including healthcare performance data and proprietary claims data, to create a comprehensive healthcare intelligence ecosystem [4][5] Group 2: Enhanced Analytics and Decision-Making - The collaboration enhances Strata's data capabilities, enabling healthcare organizations to make more informed strategic decisions that improve patient care and reduce costs [3][5] - By combining claims data with demographic data, healthcare leaders can generate more accurate volume projections and identify patient behavior patterns, aiding in strategic decision-making [6][7] Group 3: Future-Proofing and Scalability - Strata's initiative to collaborate with Snowflake is part of a strategy to future-proof its solutions amid growing customer data requirements, moving from legacy systems to a scalable cloud architecture [7][8] - The use of Snowflake's capabilities allows Strata to scale operations and deliver more accurate and efficient data and analytics capabilities for its customers [8]

Financial Data and Key Metrics Changes - Total revenue for full year 2024 was $307 million, representing a 4% year-over-year growth [7][33] - Adjusted EBITDA for full year 2024 was $26 million, a significant increase from $11 million in 2023, reflecting a 137% year-over-year growth [7][37] - Adjusted gross margin for full year 2024 was 49%, an increase of approximately 10 basis points year-over-year [36] Business Line Data and Key Metrics Changes - Technology segment revenue for full year 2024 was $195 million, with a 4% year-over-year growth [33] - Professional services revenue for full year 2024 was $112 million, representing a 3% year-over-year growth [34] - Adjusted technology gross margin for Q4 2024 was 65%, a decrease of approximately 200 basis points year-over-year due to initial deployment costs [35] Market Data and Key Metrics Changes - The company reported a dollar-based retention rate of 100% under the legacy definition for 2024, and 102% under the new definition focusing on technology and TEMs segments [15][19] - The company has over 1,000 total clients, combining platform and app clients, indicating a strong client base for future growth [12][13] Company Strategy and Development Direction - The company is focusing on cross-selling Ignite-enabled offerings to existing app clients, which is expected to drive future growth [12][19] - The company plans to exit unprofitable ambulatory TEMS pilots, representing approximately $9 million of annual professional services revenue, to prioritize profitable growth [21] - The company anticipates technology revenue to grow approximately 13% year-over-year in 2025, driven by the momentum of Ignite sales [42] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the operating environment, noting that health system operating margins are stabilizing and approaching pre-pandemic levels [18] - The company expects to add approximately 40 net new platform clients in 2025, with a focus on converting existing app clients [19][20] - Management highlighted the importance of the Ignite platform in driving future growth and improving client retention [24][80] Other Important Information - The company ended Q4 2024 with $392 million in cash and short-term investments, up from $387 million in Q3 2024 [38] - The company raised its expected adjusted EBITDA for 2025 by $2 million to approximately $41 million, reflecting better-than-expected integration progress from recent acquisitions [22] Q&A Session Summary Question: What is driving the acceleration in platform bookings in 2025? - Management noted improvements in the end market and the modular, flexible nature of the Ignite platform as key drivers for increased bookings [48][49] Question: Can you discuss the differences in the new Ignite platform versus DOS regarding annual escalators? - Management indicated that Ignite contracts typically have more modest annual escalators in the low to mid single-digit range compared to larger escalators with DOS [53] Question: How is the company managing the pace of migrations to Ignite? - Management is working closely with clients to manage migration pace responsibly, aiming to complete the majority of migrations by mid-2026 [60] Question: What is the visibility into growth in technology revenue after Q1? - Management expressed confidence in visibility for technology revenue growth, estimating approximately 10% year-over-year growth for Q1 [85]